The existence of an IgG-like molecule in avian eggs, referred to as IgY, has been well documented, and extensive research has been carried out on its characterization, production and purification. Although it is the functional equivalent of mammalian IgG, the major serum antibody found in mammals, IgY is structurally different, and has been found to exhibit several important differences when compared to mammalian antibodies, including its physico-chemical properties and immunological capabilities. Recently, considerable research has focussed on the use of IgYas an alternative to mammalian antibodies for several applications, including for immunotherapeutic applications, especially for the oral passive immunization against various bacteria and viruses. Much research has also been carried out on the use of IgYas a replacement for IgG in various immunodiagnostic and immunoaffinity purification purposes.The use of IgYoffers several advantages over polyclonal antibodies produced in mammals, including providing a much more hygienic, cost efficient, convenient, humane and plentiful source of antigen-specific antibodies.
INTRODUCTION
In 1969, Leslie and Clem reported the existence of an immunoglobulin (Ig) G-like molecule in chickens. It was the predominant serum immunoglobulin, or antibody, however its structure was slightly different than that of the mammalian serum antibody IgG, and therefore was termed IgY. It has since been found to be the principal serum antibody of birds, reptiles, and amphibians (Marchalonis, 1977) . The chicken immune system has been studied for many years, and these studies have contributed substantially to the understanding of the fundamental concepts of immunology and the development of different immunoglobulin classes (Carlander et al., 1999) .
Although functionally similar, there are several important differences between mammalian IgG and avian IgY (Sharma, 1997) , and the use of avian antibodies offers many advantages over mammalian antibodies. However, only a small fraction of antibodies currently used in laboratories are of avian origin. This could be due to a lack of information or experience with the production and puri®cation techniques involved, or the problems associated with keeping chickens, compared to smaller animals which may more conveniently be housed in a laboratory setting (Hanley et al., 1995; Schade et al., 1996) . The production of speci®c IgY against many different antigens has been studied, and its application as an immunotherapeutic agent, including its use for the oral passive immunization against enteric pathogens, has been extensively reported. Due to its distinctness from IgG, IgY has also been found to be advantageous in several immunodiagnostic techniques, as well as in immunoaf®nity puri®cation, in many cases replacing IgG.
Traditionally, commercially available polyclonal antibodies have been produced in mammals such as mice, rats, rabbits, sheep, goats, and horses, and are generally obtained from sera after immunization of these animals . However, these antibodies cannot be prepared on an industrial scale because of the dif®culty in obtaining large quantities of blood, and concerns about animal welfare. The use of hybridoma technology has been used for the preparation of monoclonal antibodies, however it is still far from the successful commercialization of therapeutic monoclonal antibodies due to the expensive cost (Wang and Imanaka, 1995) . Bovine colostrum or colostral antibodies have also been examined (Crabb, 1998) , however their quantity and antibody speci®city have limitations. Some of the real or potential applica-tions of antibodies, especially for immunotherapeutic purposes, will require kilogram quantities of highly puri®ed antibody, therefore cost-ef®cient methods of producing large quantities of speci®c antibodies are required. Recently, the chicken has attracted considerable attention as an alternative source of antibodies. IgY is deposited in the egg yolk in large quantities (Janson et al., 1995) , and it can be easily puri®ed from the yolk by simple precipitation techniques (Gassmann et al., 1990) , making chickens an ideal source for speci®c polyclonal antibodies.
Here we review several aspects of avian immunoglobulins and the avian immune system, including the structure, production and puri®cation of IgY, as well as the many current and potential applications of IgY, especially in the areas of immunotherapy and immunodiagnostics.
AVIAN EGG FORMATION
Under modern husbandry conditions, a chicken can lay an average of 250 ± 280 eggs per year. The egg is the largest biological cell which originates from one cell division, and is composed of various important chemical substances for the next generation of birds. An egg is composed of three main parts, the shell, albumen and yolk. The yolk is surrounded by an albumen layer and compartmentalized by an eggshell. The formation of an egg involves the conversion of the feed into egg constituents through a number of intricate and highly coordinated steps as a storehouse of nutrients. The hen normally starts laying at 16 ± 26 weeks of age. The reproductive system of the hen, shown in Figure 1 , consists of the ovary and oviduct (Romanoff and Romanoff, 1949) . The ovary, which is the site of assembly of the yolk, is a small organ. When the chicken becomes mature (about 150 days old), the ovary has grown to about 7 g, and rapidly increases to about 40 g (around 170 days old) (Epple and Steson, 1980) . A mature ovary contains many oocytes, and at least 600 ± 700 of them will become mature yolk. Each oocyte becomes a follicle after being covered with a granular layer. The follicles in the ovary are surrounded by the hen's veins (Burley and Vadehra, 1989) . Yolk constituents are synthesized in the liver and they are transported to the follicular walls in the blood. The follicle undergoes a rapid development during which most of the yolk is deposited 6 ± 10 days prior to ovulation, when suf®cient yolk has accumulated. The follicle in the ovary is ovulated into the oviduct where the yolk is enveloped in albumen and the shell. It takes 24 ± 27 hours for this development. In laying hens, the oviduct is 40 ± 80 cm long with an average weight 40 g and consists of ®ve regions, infundibulum, magnum, isthmus, uterus and vagina (Burley and Vadehra, 1989) . The infundibulum is the top portion of the oviduct, with a broad funnel shaped anterior end (8 ± 9 cm) and a narrow posterior end to receive the ovulated follicles. The ovulated follicle is held for 15 ± 30 minutes, where the yolk probably acquires the outer layer of the vitelline membranes and the chalaza layer of the albumen (Burley and Vadehra, 1989) . The albumen-secreting region is the largest part of the oviduct, about 30 cm long and the follicle is held here for 2 ± 3 hours while the egg albumen is secreted to cover the yolk. The isthmus is about 11 cm long and the shell membranes are synthesized here. The egg yolk enveloped with albumen is immediately wrapped by the membrane. The complete synthetic process of the shell formation takes place in the uterus (shell gland) for about 20 hours, while calcium from the blood is deposited to the shell by assembling a crystalline-like calcium structure on the shell membranes. However, its mechanism still is not well understood. The vagina is the last portion of the oviduct, and the end of the vagina connects with the cloaca. It takes only 5 minutes for the egg to pass through this portion. Shell eggs consist of about 9.5% shell, 63% albumin, and 27.5% yolk. The total solids content of egg yolk is generally around 50%, but can vary with the age of the hen and the storage of the shell eggs. The major constituents of the solid matter of yolk are proteins and lipids, present mainly in the form of lipoproteins (Li-Chan et al., 1995) . Their relative amounts can be seen in Table 1 . The yolk can be separated by high speed centrifugation into sedimented granules and a clear¯uid supernatant called plasma. Granules are composed of 70% a-and b-lipovitellins, 60% phosvitin, and 12% low-density lipoproteins (Burley and Cook, 1961) . The plasma is divided into the low-density lipoprotein fraction (33%) and the water soluble fraction (WSF) (5%), which contains the livetins, which are lipid-free globular proteins, including g-livetin, also referred to as IgY (Li-Chan et al., 1995) .
AVIAN EGG ANTIBODIES

Avian immune system
The chicken immune system consists of the Bursa of Fabricius, bone marrow, spleen, thymus, the Harderian gland, lymph nodes, circulating lymphocytes, and various lymphoid tissues. The thymus serves as the primary lymphoid organ for T-cell differentiation, while the antibody-synthesizing B-cells are produced in the Bursa of Fabricius (Sharma, 1997; Carlander et al., 1999) . The spleen is the centre for plasma cell proliferation and memory B-cells (Carlander et al., 1999) .
The immune system of vertebrates has the ability to produce an exceedingly high number of different antibody molecules, through the existence of multiple variable (V), diversity (D) and joining (J) elements in the genome (the germ line repertoire), as well as existence of somatic recombination processes and point mutations (Reynaud et al., 1985; Parvari et al., 1988) . However, B-cell formation and generation of diversity are signi®cantly different in the chicken as compared to mammals. The use of such combinatorial diversity is restricted in the chicken as the rearrangement of immunoglobulin genes is not an ongoing process, rather it takes place as a single wave during early embryogenesis. Therefore, the total number of rearrangements from which the chicken B-cell repertoire may be generated is limited to the number of Bcell precursors in the bursa (Reynaud et al., 1989 (Reynaud et al., , 1991 , estimated to be around 2-3610 4 cells (Pink et al., 1985) . Avian antibodies contain both heavy (H) and light (L) chains that are encoded by two unlinked loci. In the light chain locus there are only single gene segments each for the V and J regions. The heavy chain has only one segment each for V and J regions, and about 15 D segments (Sharma, 1997) . Therefore rearrangement contributes little diversity in chicken Bcells, in contrast to mammals, because there are only single gene segments for the V and J regions. Only the D segments serve to introduce a combinatorial factor of diversity (Reynaud et al., 1985 (Reynaud et al., , 1987 (Reynaud et al., , 1989 . Birds instead attain antibody diversity using sequences of pseudogenes (25 for the light chain and around 100 for the heavy chain) in a process of gene conversion in which segments of pseudogenes are inserted into the V region (Reynaud et al., 1987 (Reynaud et al., , 1989 Sharma, 1997) . In this way, despite the fact that chickens have an extremely limited number of immunoglobulin genes, compared to mammals, they are capable of producing a wide range of immune responses and diverse antibody molecules (Sharma, 1997) . 
Biosynthesis
Three immunoglobulin classes have been shown to exist in the chicken: IgA, IgM, and IgY. The IgA and IgM are similar to mammalian IgA and IgM. Chicken IgY is the functional equivalent of IgG, the major serum antibody found in mammals, and makes up about 75% of the total antibody population (Carlander et al., 2000) . The serum concentrations of IgY, IgA, and IgM have been reported to be 5.0, 1.25, and 0.61 mgyml, respectively (Leslie and Martin, 1973) . In mammals, the transfer of maternal antibodies can take place after birth, however in the chicken, the maternal antibodies must be transferred to the developing embryo, to give acquired immunity to the chick (Carlander et al., 1999; Sim et al., 2000) . Antibody, speci®cally IgA and IgM, is secreted into the ripening egg follicle and is incorporated into the egg white in the oviduct along with the egg albumen secretion. Serum IgY is selectively transferred to the yolk via a receptor on the surface of the yolk membrane which is speci®c for IgY translocation (Loeken and Roth, 1983; Tressler and Roth, 1987; Morrison et al., 2002) . Egg white contains IgA and IgM at concentrations of around 0.15 and 0.7 mgyml, respectively, whereas the yolk may contain from 5 to 25 mgyml of IgY (Rose et al., 1974; Schade et al., 1991; Li et al., 1997) . Mammalian equivalents of IgE and IgD have not been identi®ed in chickens (Sharma, 1997) .
Structure of immunoglobulin Y
Although similar in function, the structure of IgY is signi®cantly different than that of mammalian IgG (Carlander et al., 1999) (Figure 2 (Warr et al., 1995) . The content of b-sheet structure in the constant domains of IgY has been reported to be lower than that of IgG, and the¯exibility between the Cn1 and Cn2 domains, corresponding to the hinge region of IgG, is less than that of IgG (Shimizu et al., 1992) . Unlike IgG, IgY has two additional Cys residues, Cys331 and Cys 338, in the Cn2 Cn3 junction, which likely participate in the inter-n chain disul®de linkages (Warr et al., 1995) .
Both IgG and IgY are known to contain Asn-linked oligosaccharides, however the structure of oligosaccharides in IgY differ from those of any mammalian IgG, containing unusual monoglucosylated oligomannose type oligosaccharides with Glc 1 Man 7 ± 9 GlcNAc 2 structure (Ohta et al., 1991; Matsuura et al., 1993) .
Furthermore, the isoelectric point of IgY is lower than that of IgG (Polson et al., 1980a) , IgY does not associate with mammalian complement, and the binding of IgY with human and bacterial Fc-receptors on cell surfaces is less than that of IgG (Gardner and Kaya, 1982) . IgY does not bind to Staphylococcus protein A or Streptococcus protein G (Kronvall et al., 1974; Carlander et al., 1999) or rheumatoid factors (RF) (Larsson and Sjo Èquist, 1988) Warr et al. (1995) ).
Hinge region
Potential switch regions differences between IgG and IgY are summarized in Table 2 .
Origins of immunoglobulin Y
Although IgM is the only universally distributed antibody, and is therefore believed to be the precursor for all immunoglobulin classes, current evidence suggests that IgY may have instead been the immediate progenitor of both IgG and IgE (Warr et al., 1995) . IgY possesses the both the properties of IgG and IgE, in that it is the major serum antibody, similar to IgG, and it possesses the ability to mediate anaphylactic reactions, like IgE. The cloning and sequencing of the genes encoding the H and L chains of IgY has been carried out, and the structure of these polypeptides has been determined (Reynaud et al., 1983; Parvari et al., 1988 ) . The similarity of IgY to IgE is apparent in terms of the number of C H domains, and the number and organization of intradomain and interchain disul®de bonds. As well, amino acid sequence data supports an evolutionary hierarchy in which IgE and IgG may have arisen from IgY (Warr et al., 1995) . The properties of IgY, IgG, and IgE can be seen in Table 3 . It has been suggested that the functions of IgY may have been maladaptive, and therefore through evolution gave rise to the superior IgG. Compared to IgG, IgY has limited diversity and af®nity maturation. It also does not have the ability to precipitate or agglutinate multivalent antigens, unless at high salt concentrations (around 1.5 M) (Hersh and Benedict, 1966) , perhaps due to steric hindrance caused by the closely aligned Fab arms of the IgY molecule. High salt concentrations may serve to release the Fab arms, permitting agglutination. This would support the theory that the IgG hinge region arose from the condensation of the C H 2 domain of the IgY, conferring additional¯exibility and functional diversity on the IgG (Warr et al., 1995) .
Production and puri®cation of immunoglobulin Y
Chicken eggs present an ideal alternative antibody source to mammals, as the IgY in the chickens' blood is transported to the egg and accumulates in the egg yolk in large quantities. Hens usually lay about 280 eggs in a year. Egg yolk contains a considerable amount of IgY, around 100 ± 150 mgyegg (Rose et al., 1974) . Therefore, an immunized hen yields more than 40 g of IgY a year through eggs, equivalent to that from 40 rabbits. Jensenius et al. (1981) reported that IgY corresponding to almost half a liter of serum may be recovered from a chicken in one month. This is 5 ± 10 times higher than that from the blood of a rabbit. Over a period of slightly less than 6 weeks, 298 mg of speci®c IgY against Echino coccusgranulosus was obtained from eggs, compared to only 16.6 mg from the rabbit's blood, 18 times more from yolk (Gottstein and Hemmeler, 1985) . Separation of IgY from egg yolk has been extensively studied. Egg yolk is a¯uid emulsion with a continuous phase of lipoprotein particles. Egg yolk Based on Gottstein and Hemmeler (1985) and Schade et al. (1991) . Adapted from Barrett (1983) , Benjamini et al. (1996) , and Janeway and Travers (1996) .
a From Ohta et al. (1991) .
lipids therefore exist as lipoproteins (Burley and Cook, 1961) . The major problem in isolating IgY from egg yolk is separating the lipoproteins from egg yolk prior to puri®cation of the IgY. Based on this strategy, many puri®cation methods of IgY have been reported, and are summarized in Table 4 . Several methods have been reported using water dilution, followed by centrifugation or ultra®ltration, to isolate the water soluble fraction (WSF) (Akita and Nakai, 1992; Nakai, 1996, 1998) . This method relies on the aggregation of yolk lipoproteins at low ionic strengths, as reported by Jensenius et al. (1981) . Likewise, freezing and thawing of diluted yolk, which results in the formation of lipid aggregates that are large enough to be removed by conventional low speed centrifugation (Jensenius and Koch, 1993) , has also been employed, often as a preliminary puri®cation step, and was recently reported by Deignan et al. (2000) to result in a purity of around 70%. For these dilution methods, pH and extent of dilution are very important for optimal IgY recovery, and Nakai et al. (1994) found that the best results were obtained using a six-fold water dilution, at pH 5.0. Similar to IgG puri®cation, ammonium sulfate precipitation has also been reported for the puri®cation of IgY from WSF, following lipoprotein precipitation (Akita and Nakai, 1992; Svendsen et al., 1995) . Other methods of IgY separation include: lipoprotein separation by ultracentrifugation (McBee and Cotterill, 1979) , delipidation by organic solvents (Bade and Stegemann, 1984; Polson et al., 1985; Hatta et al., 1988; Polson, 1990; Kwan et al., 1991; Horikoshi et al., 1993; McLaren et al., 1994; Svendsen et al., 1995) , lipoprotein precipitation by polyethylene glycol (Polson et al., 1980b, Akita and Nakai, 1993; Svendsen et al., 1995) , sodium dextran sulfate (Jensenius et al., 1981; Akita and Nakai, 1993) , and dextran blue (Bizhanov and Vyshniausskis, 2000) , and natural gums such as xanthan gum (Akita and Nakai, 1993a ) and sodium alginate (Hatta et al., 1990) . Chang et al. (2000) recently reported the precipitation of over 90% of lipoproteins from yolk using lcarrageenan, sodium alginate, carboxymethyl cellulose, and pectin. Ion exchange chromatography has also been reported as a ®nal step in IgY puri®cation (McCannel and Nakai, 1990; Akita and Nakai, 1992; Fichtali et al., 1992 Fichtali et al., , 1993 , as well as hydrophobic interaction chromatography (Hassl and Aspock, 1988) . Because of the failure of IgY to bind proteins A and G, and its sensitivity to traditional af®nity puri®cation conditions, several other methods of af®nity chromatography have been examined for the puri®cation of IgY, including immobilized metal ion af®nity chromatography (McCannel and Nakai, 1989; Greene and Holt, 1997) , thiophilic interaction chromatography (Hansen et al., 1998) , af®nity chromatography using alkaline conditions (Kuronen et al., 1997) , and synthetic peptide ligands, designed speci®cally for immobilizing antibodies (Fassina et al., 1998; Verdoliva et al., 2000) . As well, Erhard et al. (1996) described a method for the puri®cation of mouse IgG subclass speci®c IgY using indirect af®nity chromatography with protein G Sepharose.
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Jennifer Kovacs-Nolan and Yoshinori Mine Hassl and Aspock, 1988 Due to the prevalence of individuals with allergies to egg proteins, the presence of extraneous egg proteins in IgY preparations designed for food or nutraceutical use must be taken into consideration, and the development of thorough puri®cation procedures is therefore of utmost importance. Akita and Nakai (1993b) also suggested the use of enzymatic digestion of IgY, to remove the Fc portion of the immunoglobulin molecule, which is considered the most allergenic portion, in order to further reduce the risk of an allergic response to IgY preparations.
Physico-chemical properties
IgY and IgG differ not only in structure, but also in their stability to pH, heat, and proteolytic enzymes. Although the stability of both immunoglobulins was similar when subjected to alkaline conditions, IgY showed much less stability than that of rabbit IgG to acid denaturation. Shimizu et al. (1992 Shimizu et al. ( , 1993 found that the activity of IgY was decreased by incubating at pH 3.5 or lower, and completely lost at pH 3. The rabbit IgG antibodies, on the other hand, did not demonstrate a loss of activity unit the pH was decreased to 2, and even then some activity still remained. Similar results were also observed by Hatta et al. (1993) , using IgY produced against human rotavirus. Similarly, the IgY was signi®cantly more sensitive to heating than the rabbit IgG. Shimizu et al. (1992) found that the activity of IgY was decreased by heating for 15 minutes at 70 C or higher, whereas that of the IgG did not decrease until 75 ± 80 C or higher. Hatta et al. (1993) found, using differential scanning calorimetry (DSC), that the temperature corresponding to the maximum of denaturation endotherm (T max ) was 73.9 C for IgY and 77.0 C for IgG. Shimizu et al. (1994) , however, described the addition of sugar to an IgY solution, and found high concentrations of sugar allowed the IgY to maintain activity when subjected to high heat (75 ± 80 C), low pH (3), or high pressure (5000 kgycm 2 ). IgY, like IgG, has been found to be relatively resistant to trypsin and chymotrypsin digestion, but sensitive to pepsin digestion (Shimizu et al., 1988) . Hatta et al. (1993) found that almost all of the IgY activity was lost following digestion with pepsin, however activity remained even after 8 hours incubation with trypsin or chymotrypsin. Otani et al. (1991) found that IgY was, however, more susceptible to digestion with trypsin, chymotrypsin and pepsin than IgG. The proteolytic digestion of antibodies is a common technique, used to remove the cross-reacting Fc portion of the antibody molecule. Akita and Nakai (1993b) noted further differences between IgY and IgG, with the peptic digestion of IgY resulting in mainly monovalent Fab' fragments, while the peptic digestion of IgG yields the bivalent F(ab') 2 fragments.
The structural factors resulting in the stability differences of the two immunoglobulins are unknown, as immunoglobulins are large, complicated molecules, composed of heterogeneous polypeptides. Shimizu et al. (1992) predicted that the lower content of b-structure in IgY may indicate that the conformation of IgY is more disordered and therefore less stable than mammalian IgG. The lack of a hinge region in IgY could be another factor affecting molecular stability. The lower¯exibility of the Cn1 and Cn2 domains of IgY, as compared to the hinge region of IgG, may cause the rapid inactivation of the antibody by the various treatments, because the¯exibility of the hinge region is considered to in¯uence the overall properties of immunoglobulin molecules (Pilz et al., 1977) .
Advantages of immunoglobulin Y
The use of chickens for the production of polyclonal antibodies provides several advantages over the traditional method of producing antibodies in mammals. In contrast to mammalian serum, egg yolk contains only the single class of antibody, IgY, which can be easily puri®ed from the yolk by simple precipitation techniques (Gassmann et al., 1990) . The phylogenetic distance between chickens and mammals renders possible the production of antibodies, in chickens, against highly conserved mammalian proteins, that would otherwise not be possible in mammals, and much less antigen is required to produce an ef®cient immune response . Chicken antibodies will also recognize different epitopes than mammalian antibodies, giving access to a different antibody repertoire than with mammalian antibodies (Carlander et al., 1999) . As well, the method of producing antibodies in hens is much less invasive, requiring only the collection of eggs, rather than the collection of blood, and is therefore less stressful on the animal (Schade et al., 1991) , and sustained high titres in chickens reduce the need for frequent injections (Gassmann et al., 1990) . The animal care costs are also lower for the chicken compared to that for mammals, such as rabbits (Carlander et al., 2000) . Hens therefore provide a more hygienic, cost ef®cient, convenient, and plentiful source of antibodies, as compared to the traditional method of obtaining antibodies from mammalian serum (Gassmann et al., 1990; Carlander et al., 2000) . Nakai et al. (1994) estimated that the productivity of antibodies in hens is nearly 18 times greater than that by rabbits based on the weight of antibody produced per head. Because of the high yolk IgY concentrations, over 100 mg of IgY can be obtained from one egg (Akita and Nakai, 1992) . A laying hen produces approximately 20 eggs per month, therefore over 2 g of IgY per month may be obtained from a single chicken (Carlander et al., 1999) . In the egg, IgY is stable for months, and once puri®ed it may be stored for years in the cold . As the industrial scale automated collection and separation of eggs is currently carried out, the large-scale production of speci®c IgY for immunotherapeutic purposes is feasible (Cotterill and McBee, 1995) . Similarly, vaccination of chicken¯ocks has long been used to control avian infections (Sharma, 1999) , making the injection of chickens required for large-scale antibody production also feasible.
APPLICATIONS OF IMMUNOGLOBULIN Y
Immunotherapeutic applications of IgY
Although it is a recent concept in human medicine, passive immunization using speci®c antibodies has been studied extensively in animals, and presents an attractive approach to establish passive immunity against pathogens in both humans and animals (Carlander et al., 2000) . In the past, immunotherapy was carried out via the systemic or intravenous administration of speci®c antibodies, for such applications as a targeting agent for cancer diagnosis and therapy, the inactivation of toxic substances including drugs, and as passive immunotherapy for neoplastic or infectious diseases (Reilly et al., 1997) . However, there has been increasing interest in the oral administration of speci®c antibodies for localized treatment of infections (Reilly et al., 1997) . The increase in antibiotic-resistant bacteria (Crabb, 1998; Wierup, 2000) , and the desire to treat pathogens that do not respond to antibiotics (Carlander et al., 2000l) , such as viral pathogens, along with the escalating number of immunocompromised individuals (Casadeval and Scharff, 1995) has prompted much research into the administration of speci®c antibodies as an alternative to antibiotics and antimicrobial chemotherapy to treat infections. It is for this reason that much of the IgY research carried out has been with regard to immunotherapy. The potential applications of IgY for the prevention and treatment of infections caused by pathogenic bacteria and viruses have been studied at length (Table 5) , and are discussed below.
Human rotavirus (HRV) has been identi®ed as the major causative agent of acute infantile gastroenteritis (Yolken et al., 1988) , infecting up to 90% of children under the age of three and resulting in more than a million deaths annually (Prasad et al., 1990; White and Fenner, 1994) . Characteristically localized to the epithelial cells of the gastrointestinal tract, HRV causes a shortening and atrophy of the villi of the small intestine (Kapikian and Chanock, 1996) , resulting in decreased water absorption, leading to severe diarrhoea and vomiting, and eventually death due to dehydration (Ludert et al., 1996; Hochwald and Kivela., 1999) . Yolken et al. (1988) found that the oral administration of antibodies isolated from the eggs of chickens immunized with three different serotypes of rotavirus (mouse, human and monkey) were capable of preventing rotavirus-induced diarrhoea in mice infected with murine rotavirus, whereas IgY isolated from the eggs of unimmunized chickens failed to prevent rotavirus infection. Using an HRV infection model in suckling mice, Hatta et al. (1993) reported that anti-HRV IgY decreased the incidence of rotavirus-induced diarrhoea in mice, both when administered before and after HRV challenge, suggesting its use for both therapeutic and prophylactic applications. Similarly, Ebina (1996) also observed the prevention of HRV-induced symptoms in mice using anti-HRV IgY. Therefore, anti-HRV IgY has the potential to signi®cantly reduce the morbidity and mortality associated with HRV infection. Recently the production of speci®c IgY against recombinant HRV coat protein VP8*, a cleavage product of the rotavirus spike protein, VP4, was reported (Kovacs-Nolan et al., 2001). VP4 has been implicated in several important functions, including cell attachment and penetration, hemagglutination, neutralization, and virulence (Mackow et al., 1988; Both et al., 1994; Desselberger and McCrae, 1994; Nejmeddine et al., 2000) , and VP8 has been found to play a signi®cant role in viral infectivity and neutralization of the virus. Using only VP8 should result in highly speci®c Neonatal calf diarrhoea, caused by bovine rotavirus (BRV), is a common disease, and signi®cant cause of mortality (Lee et al., 1995) , in cattle. The passive protection of calves against BRV infection, using anti-BRV IgY, has also been demonstrated .
Similar to BRV, bovine coronavirus (BCV) is an important cause of neonatal calf diarrhoea and acute diarrhoea in adult cattle, however BCV may be more severe as it multiplies in both the small and large intestines (Kapil et al., 1990) . Ikemori et al. (1997) examined the protective effect of anti-BCV antibodies in egg yolk and colostrum in calves challenged with BCV. They found that control calves which received no antibodies experienced severe diarrhoea and all died within 6 days after infection, whereas the calves fed milk containing egg yolk or colostrums all survived and had positive weight gain. The results indicated that orally administered egg yolk or colostral antibodies were capable of passively protecting calves against BCV infection, with the egg yolk antibodies providing a higher degree of protection, and therefore offering a more ef®cacious alternative to existing methods of passive protection against BCV.
Diarrhoea due to enterotoxigenic Escherichia coli (ETEC) is a major health problem in humans and animals. ETEC is the most common cause of enteric colibaccilosis encountered in neonatal calves (Moon et al., 1976) , piglets (Morris and Sojka, 1985) and children in developing countries and travellers to these countries (Sack, 1986) . It accounts for one billion diarrhoeal episodes annually and perhaps one million deaths each year (Sack, 1986) . One half of all travellers to developing countries also develop diarrhoea (Svennerholm et al., 1989) . It also causes signi®cant economic losses to the pig industry from both mortality and reduced growth rates, killing 1.5 ± 2.0% pigs weaned (Hampson, 1994) . The strains of ETEC which are associated with intestinal colonization and cause severe diarrhoea are the K88, K99 and 987P ®mbrial adhesins (Parry and Rooke, 1985) . It has been reported that feeding colostrum from vaccinated cows prevented diarrhoea due to infectious E. coli in infants (Hilpert et al., 1977) . Milk IgG has been used as an effective prophylactic against travellers' diarrhoea (Tacket et al., 1988) . IgY could be an alternative source of immunoglobulins for the prevention of ETEC infection, as it has been found to inhibit the binding of E. coli to the intestinal musosa (Jin et al., 1998) . IgY raised against ETEC antigen has been administered orally to piglets and has offered a potential prophylactic and therapeutic approach for controlling ETEC-induced diarrhoea (Marquardt et al., 1999) . Marquardt et al. (1999) found that the IgY titre was much higher when E.coli ®mbrial antigen was used, rather than the whole cell (Marquart et al., 1999) . Imberechts et al. (1997) raised IgY against E.coli F18ac ®mbriae, and in vitro adhesion tests demonstrated that the IgY inhibited attachment of F18ac positive E. coli to the intestinal mucosa. The anti-F18ab antibodies were also found to diminish cases of diarrhoea and death in animals infected with F18ac positive E. coli. Yokoyama et al. (1992) studied the passive protective effect of IgY against ETEC infection in neonatal piglets. Orally administered IgY was found to protect in a dose dependent manner against infection with each of the three strains of E. coli in passive immunization trials. They also demonstrated that E. coli K88, K99 and 987P strains adhered equally to porcine duodenal and ileal epithelial cells but failed to so in the presence of homologous anti®mbrial IgY (Yokoyama et al., 1992a; Ikemori et al., 1993) . In another animal feeding study, 21 day old pigs were challenged with a dose of the ETEC (10 12 cfu). IgY was administered to the piglets in milk three times a day for 2 days. Control piglets developed severe diarrhoea within 12 hours and 30% of the pigs died. In contrast, the pigs given IgY exhibited no sign of diarrhoea 24 or 48 hours after treatment (Marquardt et al., 1999) . The passive protective effect of anti-ETEC IgY, in neonatal calves, against fatal enteric collibacillosis, has also been studied (Ikemori et al., 1992) . Calves fed milk containing IgY had transient diarrhoea, 100% survival and good body weight gain during the course of the study. O'Farrelly et al. (1992) also reported the prevention of ETEC in rabbits, through the oral administration of anti-ETEC IgY. Because the oral administration of anti-ETEC IgY has proven to be successful for the treatment of gastrointestinal infections of animals, the clinical application of passive immunization of IgY against diarrhoea is now being examined, to prevent and treat ETEC infection in infants.
Salmonella spp. are a signi®cant cause of food poisoning. It is estimated that 2 ± 4 million cases of salmonellosis occur in the USA annually (Bell and Kriakides, 1998) . Symptoms include fever, abdominal pain, headache, malaise, lethargy, skin rash, constipation and changes in mental state. The elderly, infants and those with impaired immune systems may develop more severe symptoms. In these cases, the infection may spread from the intestines to the blood stream and then to other sites in the body, and can cause death. Salmonella enteritidis (SE) and Salmonella typhimurium (ST), in particular, are the major agents of food poisoning (Bell and Kriakides, 1998) . Salmonella has a variety of surface components which are virulence related, including outer membrane protein (OMP) (Isibasi et al., 1988; Udhayakumar and Muthukkaruppan, 1987) , lipopolysaccharides (LPS) (Sunwoo et al., 1996; Mine, 1997) ,¯agella (Fla), and in some strains, ®mbrial antigen (Thorns et al., 1990; Thorns et al., 1992) . OMP plays a role in pathogenicity determination (Galdiero et al., 1990) , and has been used successfully for vaccine applications, in both active and passive immunization studies (Isibasi et al., 1988; Udhayakumar and Muthukkaruppan, 1987) . LPS was also shown to elicit a strong immunogenic reaction, producing large amounts of LPSspeci®c IgY, and has shown potential application for the inhibition of salmonella adhesion and prevention of disease (Sunwoo et al., 1996; Mine, 1997) . The passive protective ef®cacy of chicken IgY speci®c for OMP, LPS or¯agella (Fla) in controlling experimental salmonellosis in mice was examined. In mice challenged with SE (2610 9 cfu), antibody treatment resulted in a survival rate of 80%, 47% and 60% using OMP, LPS or Fla-specifc IgY, respectively, in contrast to only 20% in control mice. In case of ST (2610 7 ), the survival rate was 40%, 30% and 20% using OMP, LPS or Fla speci®c IgY, while it was 0% in control mice (Yokoyama, et al., 1998a) . A novel ®mbrial antigen, SEF14, produced mainly by SE and S. dublin strains, was described by Peralta et al. (1994) . Mice challenged with SE and treated with anti-SEF14 IgY had a survival rate of 77.8%, compared to a 32% survival rate in the control mice, fed normal egg yolk IgY. Salmonella infection in calves is also a worldwide problem, and two serovars, ST and S. dublin account for most salmonellosis within the ®rst 2 weeks after birth. Passive protection against ST and S. dublin was investigated by orally inoculating calves with SE or S. dublin, and administering IgY against SE or S. dublin orally 3 times a day for 7 to 10 days after challenge exposure. All control calves died within 7 ± 10 days, whereas low titer IgY treated calves had 60 ± 70% mortality, and only fever and diarrhoea, but not death, were observed in calves given the higher titer IgY (Yokoyama et al., 1998b) . IgY has also been found to inhibit the adhesion of SE to human intestinal cells, in vitro (Sugita- Konishi et al., 1996 Konishi et al., , 2000 . These results demonstrate that IgY speci®c for Salmonella spp. is protective against fatal salmonellosis, and may be clinically useful during a salmonellosis outbreak.
The passive immunization of rainbow trout (Oncorhynchus mykiss) against infection with Y. ruckeri using IgY has been studied . The Y. ruckeri is the causative agent of enteric redmouth disease, a systemic bacterial septicemia of salmonid ®sh (Stevenson et al., 1993) . Persistence of Y. ruckeri for long periods in carrier ®sh and shedding of bacteria in feces can present a continuing source of infection. If a population of carrier ®sh could be substantially cleared by oral administration of anti-Y. ruckeri antibody treatments, it may be a cost-effective alternative to slaughtering a stock of ®sh which pose a health risk. Groups of rainbow trout that had been fed anti-Y. ruckeri IgY 2 hours prior to an immersion challenge with Y. ruckeri had lower mortalities after 8 days compared with ®sh fed with normal food before the challenge. The group fed IgY appeared to have a lower number of infected ®sh after 8 days, based on organ and intestine culture. In a subsequent trial of the feeding procedures with triplicate replicates of the groups, the IgY-fed group showed lower mortalities than groups receiving normal feed . The numbers of IgY-fed ®sh carrying Y. ruckeri in intestine samples appeared lower than the normal-feed controls, regardless of whether the feeding was given before or after the challenge. The oral administration of speci®c IgY against ®sh pathogens with feed would provide an alternative to methods using antibiotics and chemotherapy for prevention of ®sh diseases in ®sh farms. Moreover, the oral feeding of active IgY would be a novel approach for preventing viral infection diseases of ®sh because no medicine has been reported to be effective.
Edwardsiella tarda is another important ®sh pathogen, which is spread by infection through the intestinal mucosa. Edwardsiellosis in Japanese eels is a serious problem for the eel farming industry, and egg yolk antibodies have been investigated for the prevention of this infectious disease, as treatment with antibiotics has been found to promote the growth of bacterial-resistant strains (Hatta et al., 1994) . Eels were challenged with E. tarda (10 5 ± 10 6 cfu), and anti-E. tarda was then orally administered. The infected eels died within 15 days, whereas the eels given IgY survived without any symptoms of E. tarda infection, suggesting that the orally administered anti-E. tarda IgY may provide an effective approach to prevent E. tarda infection in eels (Hatta et al., 1994; Gutierrez et al., 1993) .
Streptococcus mutans serotype c is thought to be the principal causative bacterium of dental caries in humans. The molecular pathogenesis of S. mutansassociated dental caries involves a series of binding events that eventually lead to the accumulation of suf®cient numbers of these cariogenic bacteria to cause disease (Hamada and Slade, 1980) . Chicken antibodies against S. mutans MT8148 serotype c or cell-associated glucosyltransferase were prepared and tested against dental caries (Otake et al., 1991; Hamada et al., 1991; Chang et al., 1999) . Consumption of a cariogenic diet containing more than 2% IgY-containing yolk powder resulted in signi®cantly lower caries scores (Otake et al., 1991) , and effective passive protection for the prevention of colonization of S. mutans in the oral cavity. It has also been reported that mouth rinse containing IgY speci®c to S. mutans was effective in preventing the dental plaque of humans in vitro and in vivo (Hatta et al., 1997a) . Recently, Smith et al. (2001) produced IgY against the glucan binding protein B (GBP-B) of S. mutans. GBPs are believed to be involved in S. mutans bio®lm development, and antibodies against GBP-B appear to have the potential to modulate infection and disease caused by S. mutans (Smith et al., 2001) . Using a rat model of dental caries, they found that those rats treated with anti-GBP-B IgY displayed a decrease in S. mutans accumulation, as well as a decrease in the overall amount of dental caries, as compared to control rats. These studies indicate that IgY against S. mutans, or its components, may act to interfere with S. mutans accumulation, and control plaque and the subsequent oral health problems associated with plaque accumulation.
In addition, speci®c IgY has been shown to be effective at preventing and treating several other pathogens. Sugita-Konishi et al. (1996) found that speci®c IgY was capable of preventing the pathogenesis of Pseudomonas aeruginosa and Staphylococcus aureus. Its use has also been suggested for the passive protection of chicks against infectious bursal disease virus (IBDV) (Eterradossi et al., 1997) , and for the protection against porcine epidemic virus (PEDV) in piglets (Kweon et al., 2000) .
Diagnostic applications of immunoglobulin Y
In addition to their therapeutic importance, polyclonal antibodies are of great importance in biological and medical research, where they serve as essential components in a variety of diagnostic systems used for the qualitative and quantitative determination of a wide range of substances . Polyclonal IgG has long been the antibody of choice for such diagnostic applications, likely due to tradition . The antigen-binding speci®city of IgY is comparable to IgG, and they both can detect antigens with high speci®city (Hatta et al., 1997b) , however, IgY presents several advantages over IgG. As mentioned previously, due to evolutionary differences, the use of chickens for antibody production allows the production of antibodies against conserved mammalian proteins, and can result in an enhanced immune response not possible in mammals. It has also been suggested that, for this reason, chicken antibodies will bind to more epitopes on a mammalian protein, resulting in an ampli®cation of signal in immunological assays (Olovsson and Larsson, 1993) , as well as a diversi®ed antibody repertoire (Carlander et al., 1999) .
The use of IgY can also signi®cantly reduce crossreactivity and interference problems in immunological assays. Cross-reactivity in a multi-antibody assay may occur between IgG from different mammalian species. Because IgY is so different than IgG, no crossreactivity should occur, and background will be reduced (Carlander et al., 1999) . The use of IgY in immunological assays of serum samples can eliminate the interference and false positives normally experienced when using IgG. Newly obtained human serum samples often contain an active complement system, which would be activated by mammalian antibodies. IgY, on the other hand, does not activate the human complement system, and therefore its use can eliminate the interference that would be caused by IgG (Larsson et al., 1992a) . Human serum samples may also contain rheumatoid factor (RF) and human antimouse IgG antibodies (HAMA), which are well-known causes of false positive reactions in immunological assays (Carlander et al., 1999) . RF is an autoantibody that reacts with the Fc portion of IgG, and HAMA can be found naturally in human serum, or in individuals treated with mouse antibodies for therapeutic purposes, and will bind to any mouse antibodies being used in an immunoassay. Both RF and HAMA may interfere by mimicking antigen activity or forming immune complexes with other antibodies being used in the assay (Carlander et al., 1999) . IgY does not react with RF (Larsson and Sjo Èquist, 1988; Larsson et al, 1991) or HAMA (Larsson and Mellstedt, 1992) , and their use has been suggested in place of IgG for immunological assays dealing with human serum. The Fc portion of mammalian IgG may also interact with the Fc receptor, found on many types of blood cells and bacteria. IgY does not interact with Fc receptors, and can therefore be used to avoid interference due to Fc binding (Carlander et al., 1999) . Finally, as IgY does not bind protein A or G, it can be used to detect these without interference, as would otherwise be encountered when using IgG (Larsson et al., 1992b) , and its use has been described for the detection and quanti®cation of protein A in mouse monoclonal antibody preparations which have been puri®ed using protein A (Godfrey et al., 1992) .
Chicken antibodies have been used in many recent diagnostic applications, including: diagnosis of gastric cancer (Noack et al., 1999) , detection of breast and ovarian cancer markers (Grebenschikov et al., 1997; Lemamy et al., 1999; Al-Haddad et al., 1999) , detection of African horsesickness virus (Du Plessis et al., 1999) , determination of hepatocyte growth factor (HGF) in serum and urine (Ohnishi et al., 2000) , Campylobacter fetus diagnosis (Cipolla et al., 2001) , detection of transforming growth factor (TGF) in biological¯uids (Danielpour and Roberts, 1995) , determination of reactants of in¯ammation (which would otherwise interfere with mammalian antibodies) (Rieger et al., 1996) , detection of Bordetella bronchiseptica (Hlinak et al., 1996) , and for the detection of human serum antigens using surface plasmon resonance (SPR) (Vikinge et al., 1998) . Its use has recently been suggested for the detection of Human Papillomavirus for the early detection of cervical cancer (Di Lonardo et al., 2001) , for the detection of the protein YRL-40 as a marker for disease models of arthritis, cancer, atherosclerosis, and liver ®brosis (De Ceuninck et al., 2001) , and for use for hemoclassi®cation (Gutierrez Calzada et al., 2001) .
Immunoglobulin Y in immunoaf®nity chromatography
Immunoaf®nity chromatography involves the isolation and puri®cation of target molecules, using immobilized antibodies directed against the target molecule. Due to the highly speci®c nature of the antibodyantigen interaction, immunoaf®nity chromatography allows for the puri®cation of speci®c molecules from complex starting materials. The widespread use of this process on a large scale, however, has been limited by the high cost of the technique, and parameters relating to the production of antibody and the ef®ciency of immobilization (Li-Chan, 2000) . As chickens may be used to produce large quantities of highly speci®c antibodies, IgY would be an ideal replacement for other polyclonal or monoclonal antibodies currently used in immunoaf®nity chromatography. Immobilized yolk antibodies have been used for the isolation of value-added proteins from dairy products, including the puri®cation of lactoferrin , and the isolation and separation of IgG subclasses from colostrum, milk, and cheese whey . Although IgY is more sensitive to low pH than IgG, Akita and Li-Chan (1998) reported that, using standard af®nity chromatography conditions (i.e. elution at low pH), an IgY immunoaf®nity column was stable, and could be reused over 50 times without signi®cant decreases in binding capacity. Alternative eluents have been examined, including highly alkaline conditions (Kuronen et al., 1997) and high concentrations of guanidine hydrochloride (Otani et al., 1991) . Kummer and Li-Chan (1998) examined several eluents and elution conditions for IgY immunoaf®nity chromatography. Different buffers (pH 2.3 ± 7.5), various salts (NaCl, (NH 4 ) 2 SO 4 , and MgCl 2 ), ethylene glycol and glycerol, were compared to the traditionally used elution buffer (containing glycine, and at pH 2.8), and a commercially available eluent, Actisep. They found that the low pH buffers, Actisep, and MgCl 2 , all dissociated IgY from immobilized IgG, however, the dissociation was to a lesser extent when dissociating IgG from immobilized IgY. As well, some denaturation was observed with MgCl 2 and Actisep, however denaturation of the IgY following exposure to low pH was not evident. To extend the use of IgY immunoaf®nity columns, Kim et al. (1999) also examined the reusability of avidin-biotinylated IgY columns, in which biotinylated IgY is held by strong non-covalent interaction on columns containing immobilized avidin.
They found that when the antibody binding activity had been reduced by prolonged use, the column could be regenerated by dissociating the avidin-biotinylated IgY complex using guanidine hydrochloride and low pH, and applying new biotinylated IgY, thereby restoring the binding activity of the column.
A number of other applications using IgY immunoaf®nity columns have been described for the puri®-cation of biological molecules from human serum, including the puri®cation of tetrachlordibenzo-pdioxin , prekallikrein (Burger et al., 1986) , and human alpha-2 antiplasmin (Lee et al., 1997) .
Others
It has been estimated that 1.7 million people are bitten or stung by venomous snakes, scorpions, jelly ®sh, or spiders each year, resulting in 40 000 ± 50 000 fatalities. The most widely used treatment of envenomation is the use of speci®c anti-venoms to neutralize the toxic and potentially lethal effects of the venom. Chicken anti-venom IgY has been produced, and was found to have a higher bioactivity than anti-venoms raised in horses (Thalley and Carroll, 1990; Almeida et al., 1998) . IgY also has a lower likelihood of producing signi®cant clinical side effects, such as serum sickness and anaphylactic shock, which can occur upon administration of mammalian serum proteins (Thalley and Carroll, 1990; Larsson et al., 1993) .
Crohn's disease and ulcerative colitis are chronic in¯ammatory bowel diseases, which are an increasing burden to hospitals and society in terms of the cost of medication and treatment, and time lost due to illness (Hay and Hay, 1992) . Standard medical care for these diseases includes anti-in¯ammatory drugs, immunosuppressants, and antibiotics, but their use is limited by side effects, immunosuppression, and incomplete ef®cacy. Immunotherapy using monoclonal mouse antibodies directed against tumor necrosis factor (TNF) has been approved for use, however it can be costly and adverse side effects have been reported in patients receiving systemic anti-TNF therapy (Sandborn and Hanauer, 1999) . Recently Worledge et al. (2000) reported that anti-TNF antibodies produced in chickens were capable of effectively treating acute and chronic phases of colitis in rats, and were also found to neutralize human TNF in vitro, indicating its possible use for the treatment of in¯ammatory bowel disease in humans in the future.
As well, the production of IgY against barley yellow dwarf virus (Hu et al., 1985) , in¯uenza virus (Cuceanu et al., 1991) , canine distemper virus (Schmidt et al., 1989) , rabies virus (Sun et al., 2001) , and mycotoxin (Kierek-Jaszczuk et al., 1997), as well as biological molecules such as antiplasmin (Lee et al., 1997) and actin (Schrader et al., 1994) have been reported.
CONCLUSIONS AND FUTURE PROSPECTS
It has long been known that chickens, like mammals, are capable of producing antigen-speci®c IgY, which functions similar to IgG, in response to an antigenic stimulus. It was not until recently, however, that the particular immunological properties of IgY were recognized, and IgY began replacing mammalian antibodies in such applications as immunodiagnostic assays and af®nity puri®cation techniques. However, that receiving the most attention has been the application of IgY as an immunotherapeutic agent. Prompted by the need to treat microorganisms which do not respond to traditional antibiotic therapy, IgY has been produced and tested against a number of bacterial and viral antigens. Treatment with IgY has been shown to provide a safer, more ef®cient, and less expensive method than antibiotics for managing disease-causing organisms. Yolk antibodies do not activate the mammalian complement system or interact with mammalian Fc receptors that could mediate in¯amma-tory response in the gastrointestinal tract (Carlander et al., 2000) . And although low levels of IgY were found in the circulation of piglets treated orally with IgY (Yokoyama et al., 1992b) , no absorption of intact antibodies, via the gastrointestinal tract, has been shown in humans (Blum et al., 1981; Losonsky et al., 1985; Eibl et al., 1988) indicating that no systemic effects would be expected following the oral administration of IgY to humans (Carlander et al., 2000) . However, few clinical trials involving the oral administration of speci®c IgY in humans have been carried out to date.
As these immunotherapeutic applications often require the continuous or frequent administration of antibodies, large quantities are required. IgY is therefore the ideal choice for the production of large quantities of conveniently puri®ed antibodies. The use of IgY is also cost-effective, with IgY costing less than $10 per gram compared to IgG which can cost upwards of $20 000 per gram . This technology will allow for new potential applications of IgY in medicine, public health, veterinary medicine, and food safety . The production of antigen-speci®c antibodies in egg yolk also has signi®cant implications for nutraceutical and functional food development. However, to be effective for such applications, methods of IgY encapsulation will need to be further examined, as there is some controversy regarding the survival of IgY through the gastrointestinal tract and its implications for human immunotherapy. This would open the door for signi®-cant advances in IgY technology, such that the use of speci®c IgY could effect the widespread prevention and treatment of enteric diseases such as those due to E. coli, Salmonella, and rotavirus.
Research continues to be carried out on potential methods of production and application of egg yolk antibodies. Romito et al. (2001) suggested the immunization of chickens with naked DNA, to elicit antigen-speci®c IgY. Using DNA rather than a protein antigen could eliminate the protein expression and puri®cation steps, and would allow the production of antibodies against pathogenic or toxic antigens. Not only are chickens useful for the production of speci®c IgY, but Mohammed et al. (1998) demonstrated the deposition of recombinant human antibodies into the egg yolk of transgenic chickens, suggesting an extension of the production of speci®c IgY in eggs. The production of monoclonal IgY has also been examined, generated through the fusion of spleen cells from immunized chickens with chicken B cells, to produce a monoclonal IgY-secreting hybridoma (Nishinaka et al., 1991; Asaoka et al., 1992; Lillehoj and Sasai, 1994; Nishinaka et al., 1996; Matsushita et al., 1998; Matsuda et al., 1999) , capable of a consistent supply of antibody with a single and known speci®city and homogeneous structure (Janeway and Travers, 1996) . Lillehoj and Sasai (1994) and Kim et al. (2001) produced monoclonal IgY against Eimeria spp., an intracellular parasite responsible for avian coccidiosis, in order to study the avian immune response to this parasite, and to aid in vaccine development, as it was thought that monoclonal antibodies from mice would not adequately re¯ect the avian immune response, due to the differences in antibody repertoire. Due to the numerous advantages of IgY mentioned previously, monoclonal IgY would be ideal for use in diagnostic applications, where monoclonal mouse antibodies have traditionally been used. Several researchers have described the production of single chain fragment variable region (scFv) monoclonal IgY via recombinant DNA technology (Yamanaka et al., 1996; Nakamura et al., 2000; Kim et al., 2001) , in order to improve upon the low levels of antibodies produced in the chicken hybridoma systems (Nakamura et al., 2000) . Using RNA extracted from chicken hybridoma cells, Kim et al. (2001) were able to express recombinant monoclonal IgY in E. coli. and reported the production of 5 ± 6 mg of IgY per litre of culture, suggesting that the production of monoclonal IgY on a large scale may be possible.
Since it is possible, using chickens, to produce antibodies against a vast array of antigens and epitopes, likely more than is possible in mammals due to the phylogenetic differences between the two, antibodies against any number of bacterial, viral, or biological antigens is possible, suggesting the signi®-cant potential of avian antibodies for further use in immunodiagnostics and identi®cation of disease markers, immunotherapy and the treatment and prevention of disease, as well as af®nity puri®cation methods.
Despite the evidence for potential immunotherapeutic applications of IgY, and the many advantages it provides with respect to IgG for immunodiagnostics and immunoaf®nity puri®cation, mammalian antibodies continue to predominately be used, perhaps in¯uenced by a lack of knowledge of the many bene®ts of IgY technology, unfamiliarity with chicken husbandry and the techniques involved in producing IgY, or simply due to convention. Tini et al. (2002) noted that considering the many bene®ts of IgY technology and its universal application in both research and medicine, it is expected that IgY will play an increasing role in research, diagnostics, and immunotherapy in the future.
